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Magnitude of the Difference Between Clinic and Ambulatory Blood
Pressures and Risk of Adverse Outcomes in Patients With Chronic
Kidney Disease
Elaine Ku, MD, MAS; Raymond K. Hsu, MD, MAS; Delphine S. Tuot, MDCM, MAS; Se Ri Bae, BA; Michael S. Lipkowitz, MD;
Miroslaw J. Smogorzewski, MD, PhD; Barbara A. Grimes, PhD; Matthew R. Weir, MD
Background-—Obtaining 24-hour ambulatory blood pressure (BP) is recommended for the detection of masked or white-coat
hypertension. Our objective was to determine whether the magnitude of the difference between ambulatory and clinic BPs has
prognostic implications.
Methods and Results-—We included 610 participants of the AASK (African American Study of Kidney Disease and Hypertension)
Cohort Study who had clinic and ambulatory BPs performed in close proximity in time. We used Cox models to determine the
association between the absolute systolic BP (SBP) difference between clinic and awake ambulatory BPs (primary predictor) and
death and end-stage renal disease. Of 610 AASK Cohort Study participants, 200 (32.8%) died during a median follow-up of
9.9 years; 178 (29.2%) developed end-stage renal disease. There was a U-shaped association between the clinic and ambulatory
SBP difference with risk of death, but not end-stage renal disease. A 5– to <10–mm Hg higher clinic versus awake SBP (white-coat
effect) was associated with a trend toward higher (adjusted) mortality risk (adjusted hazard ratio, 1.84; 95% CI, 0.94–3.56)
compared with a 0– to <5–mm Hg clinic-awake SBP difference (reference group). A ≥10–mm Hg clinic-awake SBP difference was
associated with even higher mortality risk (adjusted hazard ratio, 2.31; 95% CI, 1.27–4.22). A ≥5–mm Hg clinic-awake SBP
difference was also associated with higher mortality (adjusted hazard ratio, 1.82; 95% CI, 1.05–3.15) compared with the reference
group.
Conclusions-—A U-shaped association exists between the magnitude of the difference between clinic and ambulatory SBP and
mortality. Higher clinic versus ambulatory BPs (as in white-coat effect) may be associated with higher risk of death in black patients
with chronic kidney disease. ( J Am Heart Assoc. 2019;8:e011013. DOI: 10.1161/JAHA.118.011013.)
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S everal current guidelines recommend use of ambulatoryblood pressure monitoring (ABPM) as the gold standard
metric for the diagnosis and confirmation of hypertension in
adults.1–3 This recommendation stems from a growing body of
literature demonstrating that 24-hour ambulatory blood
pressures (ABPs) are more strongly associated with target
organ damage compared with clinic blood pressures (BPs) in
patients with chronic kidney disease (CKD).4–8
Most guidelines agree that it is normal for clinic BP to be
up to 5 mm Hg higher than ABP in the general population,
and standard definitions for the diagnosis of white-coat and
masked hypertension have been established.9–12 Many stud-
ies have demonstrated a strong association between masked
hypertension and risk of adverse cardiovascular and renal
outcomes, but white-coat hypertension has not been consis-
tently associated with adverse outcomes.11,13–17
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ORIGINAL RESEARCH
Few studies have examined whether the magnitude of the
absolute difference between clinic and ABPs among patients
with CKD confers important prognostic information. In SPRINT
(Systolic Blood Pressure Intervention Trial), large differences
between clinic and ABPs were common, especially among
patients with CKD randomized to the intensive treatment
arm.18 These differences may be important as we intensify
our approach to BP treatment in patients with CKD.12
Our objective was to examine whether the difference
between clinic and ABP measurements has prognostic impli-
cations for risk of death and end-stage renal disease (ESRD)
among participants in the AASK (African American Study of
Kidney Disease and Hypertension) Cohort Study, one of the
largest observational studies of black patients with CKD. We
hypothesized that large differences between clinic and ABP
(either positive or negative) would be associated with higher
risk of adverse outcomes among black patients with CKD.
Methods
AASK Cohort Study
We included participants from AASK Cohort Study, a National
Institutes of Health–sponsored observational study that
enrolled black patients with CKD who had not yet developed
ESRD by the end of the AASK Cohort Study.19–21 The AASK
Cohort Study began in April 2002 and ended in June 2007,
and participants had clinic BPs and ABPM performed in close
time proximity at study entry.22–24 At the start of the AASK
Cohort Study, all participants were treated to a clinic BP
target of <140/90 mm Hg based on results of the AASK
Cohort Study;21,24 the target was changed in 2004 to <130/
80 mm Hg because of updated Joint National Committee
guidelines.23,25 Of AASK Cohort Study participants, 98% (674
of a total 691) had patient identifiers that facilitated
ascertainment of ESRD and mortality outcomes. In our
current analysis, we additionally excluded 64 participants
who did not have ABPM data, deriving a final analytic cohort
of 610 participants. Informed consent was obtained at all
participating sites for participation in AASK Cohort Study and
institutional review board approval for secondary data anal-
ysis was obtained at the University of California, San
Francisco. Parent AASK Cohort Study data have been made
publicly available at the National Institute of Diabetes and
Digestive and Kidney Diseases Central Repository.26
BP Measurements
Clinic BP
Clinic BPs were obtained by certified personnel using an
aneroid device at the time of enrollment into the AASK Cohort
Study.19,22,24 Three consecutive seated readings were
obtained at each visit, and the average between the second
and third seated readings was considered the clinic BP for the
visit. The clinic BP taken from the initial AASK Cohort Study
visit that was chronologically closest to ABPM performance
was used to calculate the difference between clinic and ABPs.
More than 96% of ABPMs were performed within 90 days of
clinic BPs (median time difference=8 days).
Ambulatory BP
ABPMwas performed at the time of baseline enrollment into the
AASK Cohort Study using a SpaceLabs 90207 device, with BPs
taken every 30 minutes over a 24-hour period.5,13 Data from all
ABP monitors were sent to the AASK Central Cardiovascular
Core Laboratory and read centrally. Awake ABP readings were
considered the mean of those BPs that were taken from 6 AM to
12 AM (midnight), as diaries were not available.5
Primary Predictor
We computed the difference between clinic BPs and awake
ABP readings separately for systolic BP (SBP) and diastolic BP
(DBP; henceforth termed clinic-awake difference) as our
primary predictor of interest. If clinic BP was higher than
awake SBP readings by >5 mm Hg, this was considered a
“white-coat” effect (regardless of whether meeting criteria for
hypertension). If clinic BP was lower than awake SBP
readings, this was considered a “masked” effect (regardless
of whether meeting criteria for hypertension). Most AASK
cohort participants had a history of diagnosed hypertension
and were receiving antihypertensive therapy.19,21,24 We were
most interested in the difference between clinic and awake
ABP readings because clinic BPs would be expected to differ
more substantially from 24-hour mean ABP because of its
Clinical Perspective
What Is New?
• In this study, we found that the magnitude of the difference
between clinic and ambulatory blood pressure measure-
ments taken in close time proximity was predictive of the
risk of all-cause mortality in a cohort of black patients with
chronic kidney disease, but not with end-stage renal
disease.
What Are the Clinical Implications?
• Our findings suggest that even if a patient with chronic
kidney disease has “white-coat” elevations in blood pres-
sure, large differences between the clinic and ambulatory
readings may be prognostic of worse outcomes, and these
patients may need closer monitoring and appropriate
cardiovascular risk modification.
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inclusion of nocturnal measurements. However, we also
computed the difference between clinic and 24-hour mean
ABP readings separately (henceforth termed clinic-ABP differ-
ence) as a secondary predictor.
Outcomes
To extend ascertainment of ESRD and vital status beyond the
end of the AASK Cohort Study through to June 30, 2012, we
performed linkage of AASK Cohort Study participants with the
US Renal Data System and the Social Security Death
Index.27,28 All-cause death was our primary outcome given
the known benefit of BP control on mortality risk.29 ESRD was
a secondary outcome, as the association between BP lowering
and ESRD risk has traditionally been less robust.21,30
Statistical Analysis
We used Cox proportional hazards models starting from the
date of ABPM to determine the association between clinic-
awake (or clinic-ABP) difference with death. We first per-
formed unadjusted Cox models using cubic splines (with 3
evenly spaced knots at 21, 4.5, and 15 mm Hg for clinic-
ABP difference). We chose to begin our analysis with cubic
splines because these models allowed for greater flexibility in
modeling the association between BP and outcomes and can
be used to detect nonlinear relationships. Then, we performed
additional Cox models after categorizing the clinic-awake and
clinic-ABP systolic and diastolic differences as ≥5 mm Hg
(ie, clinic BP is lower than awake or ABP by at least
5 mm Hg), 5 to <0 mm Hg, 0 to <5 mm Hg (reference), 5
to <10 mm Hg, and ≥10 mm Hg. The reference group was
selected because of the general acceptance that clinic BPs
can be up to 5 mm Hg higher than awake ABPs and still be
considered normal.20 Although up to a 10–mm Hg difference
is the normative difference between clinic and 24-hour mean
BPs (because of inclusion of nocturnal readings), we chose to
use a 5–mm Hg difference as the reference group for both
clinic-awake and clinic-ABP differences because at lower
ranges of BPs (eg, SBP <120–130 mm Hg), the normative
difference narrows to ≤5 mm Hg.29 Furthermore, recent data
have suggested that black patients have higher nocturnal BPs,
and the current normative standards (which were not
developed in a racially diverse population) have been ques-
tioned.31
We examined the association between categories of the
clinic-awake or clinic-ABP differences (using separate models
for each predictor) with risk of death in unadjusted analyses,
followedbyamainadjustedmodel, includingage, sex, estimated
glomerular filtration rate (eGFR) by the CKD–Epidemiology
Collaboration equation,32 heart disease (defined by a combina-
tion of self-report, chart review, or baseline electrocardiogram
reading), and proteinuria (measured at cohort entry) in model 1.
In model 2, we added clinic SBP as a covariate to model 1. In
model 3, we added either mean awake SBP or mean 24-hour
ambulatorySBPasacovariate tomodel1,dependingonwhether
the primary predictor is clinic-awake SBP or clinic-ambulatory
SBP. Finally, because of the strong prognostic significance of
sleep BPs in the literature compared with other ABPs,17 we also
added sleep BPs in a sensitivity analysis in model 4. We
categorized eGFR by CKD stages (eGFR ≥45, 30–<45, or
<30 mL/min per 1.73 m2) and proteinuria (≥0.5 versus
<0.5 g/g or missing) to handle nonnormality in both variables.
We repeated all analyses using DBP differences between
clinic and ABPs. We also repeated all analyses using ESRD as
our secondary outcome.
Table 1. Characteristics of AASK Cohort Study Participants Included for Analysis by Categories of Difference Between Clinic and
Awake SBP
Characteristics
Clinic BP–Mean Awake ABP, mm Hg
White-Coat Effect Reference Masked Effect
≥10 5 to <10 0 to <5 5 to <0 ≥5
(N=93) (N=56) (N=70) (N=97) (N=294)
Age, y 60.49.3 61.28.4 59.510.9 58.59.7 60.110.6
Female sex 43 (46.2) 33 (58.9) 29 (41.4) 36 (37.1) 92 (31.3)
Heart disease 35 (35) 34 (61) 56 (58) 65 (70) 197 (67)
eGFR, mL/min per 1.73 m2 39.916.5 36.315.0 35.915.2 42.716.3 39.215.2
Proteinuria, median (IQR), g/g* 0.05 (0.02–0.1) 0.09 (0.04–0.34) 0.07 (0.03–0.26) 0.05 (0.03–0.29) 0.06 (0.03–0.32)
Randomized to strict BP control during the
AASK Cohort Study
49 (52.7) 30 (53.6) 30 (42.9) 48 (49.5) 147 (50.0)
Data are given as meanSD or number (percentage), unless otherwise indicated. AASK indicates African American Study of Kidney Disease and Hypertension; ABP, ambulatory BP; BP,
blood pressure; eGFR, estimated glomerular filtration rate; IQR, interquartile range; SBP, systolic BP.
*Missing in N=81.
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Finally, we tested for prespecified interactions by adding
interaction terms between the clinic-awake SBP difference or
clinic-ABPM SBP difference with the following: (1) baseline
clinic SBP; and separately (2) mean awake SBP (when clinic-
awake SBP difference is the primary predictor) or mean 24-
hour ambulatory SBP (when clinic-ABPM SBP difference is the
primary predictor). These analyses were designed to deter-
mine whether the magnitude of the clinic-awake or clinic-ABP
differences and their associations with death differed depend-
ing on the level of achieved SBP.
STATA14 was used for statistical analyses. For all analyses,
P<0.05 was considered statistically significant.
Results
Characteristics of the 610 AASK Cohort Study participants
are shown in Tables 1 and 2. Overall mean age was
60.5 years, 38% of the cohort were women, and mean eGFR
was 39 mL/min per 1.73 m2. Mean clinic SBP was
13420 mm Hg, and mean clinic DBP was 8012 mm Hg,
at cohort entry. In general, more women had white-coat effect
and fewer women had masked effect, but there were no
differences in age, prior BP target randomization arm, baseline
eGFR, or proteinuria between different categories of the clinic-
awake difference (Table 1). Heart disease was more prevalent
among those with masked effect compared with those with
white-coat effect. The distribution of the clinic, 24-hour ABP,
and ABP awake BPs is shown in Table 2. Approximately 24%
of patients had white-coat effect and 64% had masked effect
using the difference between clinic and awake SBP.
Risk of All-Cause Mortality
During a median follow-up of 9.9 years, 200 (of 610)
participants died. A U-shaped association was found between
the magnitude of the clinic-awake SBP difference (either
positive or negative) and the risk of death (Figure—Panel A).
Results of the association when the magnitude of the clinic-
awake difference was examined categorically are shown in
Table 3. Compared with the reference group (clinic-awake
SBP difference of 0–<5 mm Hg), participants with a clinic
SBP that was 5 to <10 mm Hg higher than awake SBP had at
least a 1.84 times greater risk of death (model 1), although
this finding did not achieve statistical significance. Those with
a >10–mm Hg higher clinic SBP than awake SBP had a 2.31
times higher risk of death (Table 3). There was no difference
in the risk of death among study participants with a clinic-
awake SBP difference of 5 to 0 mm Hg compared with the
reference group in model 1 (hazard ratio, 1.15 [95% CI, 0.59–
2.24]). However, if the clinic-awake SBP difference was
≥5 mm Hg, the adjusted risk of death was statistically
significantly higher than that for the reference group (hazardTa
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ratio, 1.82 [95% CI, 1.05–3.15]). Additional adjustment
accounting for demographics, kidney function, heart disease,
proteinuria, as well as clinic, awake, or sleep SBP did not
substantially alter findings (models 2–4, Table 3).
Similar results were found when examining the association
between clinic-systolic ABP difference and the risk of death. We
found a U-shaped association between the magnitude of the
clinic-ambulatory SBP difference (either positive or negative)
and the risk of death (Figure—Panel B). A higher risk of death
was also noted among individuals with categories of clinic-
ambulatory SBP difference of >5 mm Hg or ≥5 mm Hg in
unadjusted analysis (Table 4); with further adjustment in model
1, a ≥10– or ≥5–mm Hg difference in clinic ambulatory SBP
was statistically significantly associated with risk of death
(Table 4). Additional adjustments for clinic SBP, 24-hour mean,
or sleep SBP did not substantially alter findings (models 2–4).
We tested for but did not find significant interactions
between categories of the clinic-awake or clinic-ABP differ-
ence with baseline clinic SBP, mean awake SBP, or 24-hour
SBP (all P>0.05).
The relationship between DBP and outcomes of interest
differed from that observed for SBP. Specifically, presence of
clinicDBPhigher than ambulatoryDBP (either awakeormean24-
hour DBP in a white-coat effect) was not associated with risk of
death in our spline-based analyses (Figure–Panels C and D).
However, clinic DBP lower than ambulatory DBP (masked effect)
appeared to have a continuous and graded association with
mortality risk that was similar to that observed for SBP.When the
clinic-awake or clinic-ABPM DBP differences were categorized, a
difference ≥5 mm Hgwas statistically significantly associated
with mortality risk in adjusted analyses (data not shown).
Risk of ESRD
A total of 178 participants developed ESRD during follow-up.
The continuous relationship between the magnitude of the
clinic-awake and clinic-ABP difference with risk of ESRD is
shown in Figure S1A and S1B for SBPs and Figure S1C and
S1D for DBPs. There was no statistically significant associ-
ation between the magnitude of the clinic-awake or clinic-ABP
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Figure. Association between clinic-awake or clinic–ambulatory blood pressure (ABP) and risk of death in unadjusted models. Risk of death
based on difference between clinic and ABP monitoring (ABPM) systolic blood pressure (SBP; 24 hour and awake). A, U-shaped association
between the magnitude of the clinic-awake ABPM SBP difference and the risk of death. B, U-shaped association between the magnitude of the
clinic–24-hour mean ABPM SBP difference and the risk of death. C and D, Clinic-ABPM diastolic blood pressure (DBP) not associated with risk of
death.
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systolic or diastolic difference and risk of ESRD in unadjusted
analyses (Tables S1 and S2). In adjusted analyses, extremes
of differences (>10 or ≥5 mm Hg) in clinic-awake or clinic-
ambulatory DBP were associated with a higher risk of ESRD in
adjusted analyses, and further adjustment for ABPM param-
eters did not substantially alter results (data not shown).
Discussion
In the population with CKD, 10% to 30% of patients are
reported to have white-coat hypertension, and 30% to 60%
of patients with CKD have masked hypertension.4,8,13,33,34
However, neither masked nor white-coat hypertension can be
detected without out-of-office BP measurements, and 24-hour
ABPM remains the preferred standard measure of out-of-
office BPs.10,35 Although many observational studies have
demonstrated the prognostic significance of ABPM parame-
ters that support the routine ascertainment of ABPs, most of
these studies have either examined the prognostic signifi-
cance of individual parameters (eg, nocturnal SBP) as
continuous variables or categorized clinic BPs as white-coat,
masked, or confirmed hypertension for study.5,7,8,13,36
In this study, we found that, compared with a clinic-awake
or clinic-ABP difference of 0 to <5 mm Hg (considered a
normal difference), there was a continuous, U-shaped rela-
tionship between positive or negative absolute differences in
clinic-awake or clinic-ABP SBP measurements with mortality
risk. Specifically, when a white-coat effect was present (clinic
SBP higher than ambulatory SBP by ≥5 mm Hg), the clinic-
awake and clinic-ABP differences were strongly associated
with mortality risk in a graded manner. When a masked effect
was present (clinic SBP lower than ambulatory SBP), the
clinic-awake and clinic-ABP differences were only associated
with mortality risk if this absolute difference was ≥5 mm Hg.
These findings were not attenuated after adjustment for clinic
SBP, ambulatory SBP, sleep SBP, or proteinuria, suggesting
that the absolute difference between clinic and ABP provides
independent prognostic information beyond achieved SBP.
The magnitude of the clinic-awake or clinic-ABPM SBP
difference was not associated with risk of ESRD.
Table 3. Difference Between Clinic and Mean Awake ABP and Long-Term Risk of Death
Systolic BP, mm Hg
Fully Adjusted Models,
Hazard Ratio (95% CI)
(Clinic–Awake Ambulatory BP) N Unadjusted Model 1 Model 2 Model 3 Model 4
“White-coat effect”
≥10 93 2.30 (1.27–4.18) 2.31 (1.27–4.22) 2.10 (1.14–3.86) 2.62 (1.43–4.81) 2.53 (1.38–4.62)
5 to <10 56 2.07 (1.07–4.02) 1.84 (0.94–3.56) 1.85 (0.95–3.61) 1.98 (1.01–3.87) 1.96 (1.01–3.84)
0 to <5 70 Reference Reference Reference Reference Reference
“Masked effect”
5 to <0 97 1.04 (0.54–2.02) 1.15 (0.59–2.24) 1.25 (0.64–2.43) 1.22 (0.62–2.37) 1.21 (0.62–2.36)
≥5 294 1.82 (1.06–3.13) 1.82 (1.05–3.15) 2.14 (1.22–3.75) 1.79 (1.03–3.09) 1.76 (1.02–3.05)
Model 1: All fully adjusted models are adjusted for age, sex, heart disease, estimated glomerular filtration rate at cohort entry, and proteinuria. Model 2: Adjusted model+clinic systolic BP.
Model 3: Adjusted model+either mean awake ambulatory systolic BP (Table 3) or mean 24-hour ambulatory systolic BP (Table 4), depending on whether the difference is between clinic-
awake systolic BP or clinic–ABP monitoring systolic BP. Model 4: Adjusted model+mean 24-hour asleep systolic BP. ABP indicates ambulatory BP; BP, blood pressure.
Table 4. Difference Between Clinic and Mean 24-Hour ABP and Long-Term Risk of Death
Systolic BP, mm Hg
Fully Adjusted Models,
Hazard Ratio (95% CI)
(Clinic–Ambulatory BP) N Unadjusted Model 1 Model 2 Model 3 Model 4
≥10 104 2.34 (1.29–4.22) 2.18 (1.20–3.95) 1.95 (1.07–3.56) 2.47 (1.35–4.49) 2.36 (1.30–4.28)
5 to <10 58 1.99 (1.02–3.89) 1.59 (0.81–3.13) 1.59 (0.81–3.13) 1.72 (0.87–3.38) 1.71 (0.87–3.37)
0 to <5 77 Reference Reference Reference Reference Reference
5 to <0 91 1.31 (0.68–2.53) 1.38 (0.72–2.67) 1.50 (0.78–2.91) 1.45 (0.75–2.81) 1.34 (0.70–2.60)
≥5 280 2.07 (1.20–3.56) 1.85 (1.07–3.21) 2.20 (1.25–3.87) 1.80 (1.04–3.11) 1.69 (0.97–2.93)
Model 1: All fully adjusted models are adjusted for age, sex, heart disease, estimated glomerular filtration rate at cohort entry, and proteinuria. Model 2: Adjusted model+clinic systolic BP.
Model 3: Adjusted model+either mean awake ambulatory systolic BP (Table 3) or mean 24-hour ambulatory systolic BP (Table 4), depending on whether the difference is between clinic-
awake systolic BP or clinic–ABP monitoring systolic BP. Model 4: Adjusted model+mean 24-hour asleep systolic BP. ABP indicates ambulatory BP; BP, blood pressure.
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A few prior studies have examined the implications of the
magnitude of the difference between clinic and ABP measure-
ments in the context of variations in the response of this
difference to antihypertensive therapy, and changes to these
differences have been observed as aging occurs in populations
without CKD.36–38 Our study results extend those from prior
observations to examine the association of those differences
withmortality and ESRD, arguably outcomes of greatest interest
to patients. Consistent with prior studies that have shown that
masked hypertension is associated with risk of adverse
outcomes,39,40 we found that masked clinic-awake or clinic-
ABPM SBP differences of ≥5 mm Hg were associated with a
higher risk of death, regardless of whether absolute SBPmet the
definition for hypertension. It is possible that these findingsmay
be driven by the well-performed protocol-driven AASK clinic BP
readings, which have important prognostic value and are likely
lower than non–protocol-driven clinic BP readings.
We also found that clinic SBP readings that represented a
white-coat effect were strongly associated with the risk of
death. A few studies of patients in the general population have
suggested that presence of white-coat hypertension is
associated with higher-risk cardiovascular outcomes and
may be a precursor to the development of sustained
hypertension.40–45 Our findings are consistent with recent
studies that also demonstrated that white-coat hypertension
was not benign and was associated with cardiovascular risk
during long-term follow-up.17,46 Prior studies have noted that
the prevalence of white-coat hypertension is more common
among women in the general population,47,48 whereas
masked hypertension may be more common in men.49 Our
findings are consistent with those of the literature in the
general population, and in the setting of a new diagnosis of
hypertension, confirmation of the diagnosis using ABPM,
especially in black women, could help prevent overtreatment.
Having a large difference between clinic and ABPs may
also reflect heightened variability or “volatility” of BP
measurements or increased levels of sympathetic overactiv-
ity, which may be associated with long-term cardiovascular
risk. However, it is also possible that these findings are
specific to the black population with CKD, as little is known
about racial differences in the prognostic value of ABP in the
population with CKD. On the basis of our findings, a clinic-ABP
difference of >5 mm Hg, suggestive of white-coat phenom-
ena, should not be completely ignored as benign among black
patients with CKD. Thus, we believe that even in the presence
of white-coat hypertension, patients with CKD who exhibit a
large difference between clinic and ABPs may need closer
follow-up and intensive cardiovascular risk reduction, as these
patients are at elevated risk for death during long-term follow-
up. In contrast, those patients with smaller magnitudes of
difference (eg, <5 mm Hg) between ambulatory and clinic BPs
may be at lower risk for adverse cardiovascular events.
We did not find the difference between clinic-ABP or clinic-
awake SBP or DBP to be consistently associated with the risk
of ESRD. Prior studies of patients with CKD have also not
found ABP measurements to be consistently associated with
renal outcomes, especially after accounting for other risk
factors for CKD progression.7 Our results are overall consis-
tent with the null effects of several adult BP-lowering trials on
ESRD outcomes.21,23,29,30
The strengths of this study include the use of a well-
characterized cohort and availability of well-performed
research-grade clinic BPs and ABPs. Limitations include the
focus on a black population with hypertension-attributed CKD,
so our results may not generalize to all patients with CKD.
Also, the number of participants with white-coat effect was
smaller, and this warrants replication with a larger sample size
with a higher number of events. The AASK Cohort Study was
also unique in the long-term relationship between participants
and study coordinators who obtained BP readings, which may
have reduced white-coat effects during clinic measure-
ments.50 We also do not have causes of death and, therefore,
are unable to examine the risk of cardiovascular-related
mortality. Finally, although repeated ABPMs were performed
every 2 years during the duration of the AASK Cohort Study,
the number of participants with ABPM declined precipitously
after the baseline ABPM; and those who died would not have
had a subsequent ABPM (which may lead to survivor bias), so
we have chosen not to include analysis of subsequent ABPs in
this study.
In conclusion, the magnitude of the difference between
clinic and ambulatory SBP measurements has prognostic
significance and should be considered during BP assessments
among patients with CKD. Our results suggest that the
presence of a white-coat effect may be associated with higher
risk of death, even when clinic or ambulatory SBPs are
controlled. We believe that it is important to invest in more
widespread implementation of ABPM and efforts to obtain
consistent, high-quality, clinic BP measurements to accurately
collect data that may inform antihypertensive therapy in
patients with CKD. Further studies are needed to confirm
these findings in more racially diverse populations and to
examine whether therapeutic changes to alter clinic-ABP
differences may lead to improved outcomes.
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SUPPLEMENTAL MATERIAL
Table S1.  Difference between clinic and mean awake ambulatory blood pressure and risk of ESRD. 
N=610 Systolic BP Diastolic BP 
Difference taking 
clinic –ambulatory 
N Unadjusted Hazard 
Ratio (95% CI) 
Adjusted* Hazard 
Ratio
(95% CI ) 
Unadjusted Hazard 
Ratio (95% CI) 
Adjusted* Hazard 
Ratio 
(95% CI ) 
≥10 mm Hg 93 0.83 (0.49-1.43) 1.56 (0.88-2.76) 73 1.11 (0.61-2.02) 1.80 (0.96-3.35) 
5 to <10 mm Hg 56 0.82 (0.44-1.53) 1.06 (0.55-2.03) 73 1.57 (0.93-2.66) 2.01 (1.18-3.43) 
0 to <5 mm Hg 97 Ref Ref 124 Ref Ref 
-5 to <0 mm Hg 70 0.67 (0.39-1.16) 1.26 (0.72-2.20) 126 1.18 (0.74-1.87) 1.47 (0.92-2.34) 
≥ -5 mm Hg 294 0.78 (0.50-1.20) 1.29 (0.81-2.05) 214 1.01 (0.67-1.54) 1.60 (1.03-2.48) 
*Adjusted for age, sex, heart disease, eGFR at cohort entry, and proteinuria
ESRD=end-stage renal disease
Table S2.  Difference between clinic and mean ambulatory blood pressure and risk of ESRD. 
N=610 Systolic BP Diastolic BP 
Difference taking 
clinic –ABPM 
N Unadjusted Hazard 
Ratio (95% CI) 
Adjusted* Hazard 
Ratio 
(95% CI ) 
N Unadjusted Hazard 
Ratio (95% CI) 
Adjusted* 
Hazard Ratio 
(95% CI ) 
≥10 mm Hg 104 1.16 (0.67-2.01) 1.80 (1.01-3.21) 54 1.70 (1.01-2.87) 1.70 (1.00-2.88) 
5 to <10 mm Hg 58 1.36 (0.73-2.51) 1.63 (0.87-3.06) 64 1.18 (0.67-2.06) 1.23 (0.69-2.17) 
0 to <5 mm Hg 77 Ref Ref 119 Ref Ref 
-5  to <0 mm Hg 91 0.94 (0.52-1.68) 1.38 (0.76-2.51) 122 1.36 (0.85-2.17) 1.38 (0.86-2.21) 
≥ -5 mm Hg 280 1.19 (0.74-1.90) 1.73 (1.07-2.82) 251 1.28 (0.82-1.98) 1.71 (1.10-2.68) 
*Adjusted for age, sex, heart disease, eGFR at cohort entry, and proteinuria
ESRD= end-stage renal disease
Figure S1.  Risk of ESRD based on difference between office and ABPM systolic and diastolic (24 hour 
and awake). 
ESRD=end-stage renal disease, ABPM=ambulatory blood pressure monitoring, SBP=systolic blood pressure, 
DBP=diastolic blood pressure 
